CytomX Therapeutics Inc - ESG Rating & Company Profile powered by AI
If you work at CytomX Therapeutics Inc and you wish to use your ESG aseessment, please get in touch. This webpage of CytomX Therapeutics Inc was assembled by All Street Sevva using advanced AI. The Disclosure rating covers 17 UN Sustainable Development Goals including: 'Gender Equality', 'Climate Action' and 'Partnerships for the Goals'.
CytomX Therapeutics Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 3.5; made up of an environmental score of 4.0, social score of 1.6 and governance score of 4.8.
3.5
Low ImpactEnvironmental
Social
Governance

Peer Group Comparison
Rank | Company | SDG Transparency Score ⓘ | Performance |
---|---|---|---|
1 | Caladrius Biosciences Inc | 8.0 | High |
1 | Can Fite Biopharma Ltd | 8.0 | High |
... | ... | ... | |
1144 | Veerhealth Care Ltd | 3.6 | Medium |
1144 | iStreet Network Ltd | 3.6 | Medium |
1186 | CytomX Therapeutics Inc | 3.5 | Medium |
1186 | CRISPR Therapeutics AG | 3.5 | Medium |
1186 | Catalent Inc | 3.5 | Medium |
... | ... | ... | |
1970 | Zyden Gentec Ltd | 0.0 | Low |
1970 | iNtRON Biotechnology Inc | 0.0 | Low |
... | ... | ... |

Frequently Asked Questions
Does CytomX Therapeutics Inc have an accelerator or VC vehicle to help deliver innovation?
Does CytomX Therapeutics Inc disclose current and historical energy intensity?
Does CytomX Therapeutics Inc report the average age of the workforce?
Does CytomX Therapeutics Inc reference operational or capital allocation in relation to climate change?
Does CytomX Therapeutics Inc disclose its ethnicity pay gap?
Does CytomX Therapeutics Inc disclose cybersecurity risks?
Does CytomX Therapeutics Inc offer flexible work?
Does CytomX Therapeutics Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Does CytomX Therapeutics Inc disclose the number of employees in R&D functions?
Does CytomX Therapeutics Inc conduct supply chain audits?
Does CytomX Therapeutics Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Is there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Does CytomX Therapeutics Inc conduct 360 degree staff reviews?
Does CytomX Therapeutics Inc disclose the individual responsible for D&I?
Does CytomX Therapeutics Inc disclose current and historical air emissions?
Is there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Is executive remuneration linked to climate performance?
Does the Board describe its role in the oversight of climate-related risks and opportunities?
Does CytomX Therapeutics Inc disclose current and / or historical scope 2 emissions?
Does CytomX Therapeutics Inc disclose water use targets?
Does CytomX Therapeutics Inc have careers partnerships with academic institutions?
Did CytomX Therapeutics Inc have a product recall in the last two years?
Does CytomX Therapeutics Inc disclose incidents of discrimination?
Does CytomX Therapeutics Inc allow for Work Councils/Collective Agreements to be formed?
Has CytomX Therapeutics Inc issued a profit warning in the past 24 months?
Does CytomX Therapeutics Inc disclose parental leave metrics?
Does CytomX Therapeutics Inc disclose climate scenario or pathway analysis?
Does CytomX Therapeutics Inc disclose current and / or historical scope 1 emissions?
Are Operating Expesnses linked to emissions reduction?
Does CytomX Therapeutics Inc disclose the pay ratio of women to men?
Does CytomX Therapeutics Inc support suppliers with sustainability related research and development?
Does CytomX Therapeutics Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Does CytomX Therapeutics Inc reflect climate-related risks in its financial statements?
Is there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Is CytomX Therapeutics Inc involved in embryonic stem cell research?
Does CytomX Therapeutics Inc disclose GHG and Air Emissions intensity?
Does CytomX Therapeutics Inc disclose its waste policy?
Does CytomX Therapeutics Inc report according to TCFD requirements?
Does CytomX Therapeutics Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Does CytomX Therapeutics Inc disclose energy use targets?
Does CytomX Therapeutics Inc disclose its Renewable Energy targets?

Are emissions metrics verified by STBi?

Does CytomX Therapeutics Inc have a policy relating to cyber security?
Have a different question?
Potential Risks for CytomX Therapeutics Inc
These potential risks are based on the size, segment and geographies of the company.
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical trials for the treatment of breast cancer; CX-2029 that is in Phase II clinical trials for the treatment of squamous non-small cell lung cancer, head and neck squamous cell carcinoma, esophageal and gastro-esophageal junction cancers, and diffuse large B-cell lymphoma; BMS-986249, a CTLA-4 Probody therapeutic drug, which is in Phase I/II clinical trials for the treatment of metastatic melanoma; and BMS-986288, an anti-CTLA-4 Probody drug, which is in Phase I clinical trials for the treatment of solid tumors. It also develops CX-2043, a conditionally activated ADC targeting the epithelial cell adhesion molecule, as well as CX-904, a conditionally activated epidermal growth factor receptor for the treatment of solid tumor. The company has strategic collaborations with AbbVie Ireland Unlimited Company, Amgen, Inc., Bristol-Myers Squibb Company, ImmunoGen, Inc., Pfizer Inc., and Astellas Pharma Inc. to develop Probody therapeutics. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.